Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: Treating active drug users

Hepatology

Volumn 50, Issue 1, 2009, Pages 323-324

  Swan, Tracy ^a   Curry, Jen ^b  

^a Treatment Action Group   (United States)

^b Harm Reduction Coalition   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ILLICIT DRUG; METHADONE;

ALCOHOL ABUSE; CONTRACEPTION; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; LETTER; METHADONE TREATMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; SUBSTANCE ABUSE; UNITED STATES; ADDICTION; MEDICAL SOCIETY; NOTE; PATIENT SELECTION; STANDARD;

HEPATITIS C; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 70349724344     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23077     Document Type: Letter

References (11)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. HEPATOLOGY 2009;49:1335-1374.
2. Hagan H, Latka MH, Campbell JV, Golub ET, Garfein RS, Thomas DA, et al.; Study to Reduce Intravenous Exposures Project Team. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis 2006;42:669-672.
3. Mehta SH, Thomas DL, Sulkowski MS, Safaein M, Vlahov D, Strathdee SA. A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. AIDS 2005;19(Suppl 3):S179-S189. (Pubitemid 41682186)
4. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. HEPATOLOGY 2001;34:188-193. (Pubitemid 32591499)
5. Bruggmann P, Falcato L, Dober S, Helbling B, Keiser O, Negro F, et al.; Swiss Hepatitis C Cohort Study. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat 2008;15:747-752.
6. Cournot M, Glibert A, Castel F, Druart F, Imani K, Lauwers-Cances V, et al. Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit. Gastroenterol Clin Biol 2004;28:533-539. (Pubitemid 38917484)
7. Grebely J, Genoway K, Khara M, Duncan F, Viljoen M, Elliott D, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007;18:437-443. (Pubitemid 47381422)
8. Litwin AH, Harris KA Jr, Nahvi S, Zamor PJ, Soloway IJ, Tenore , et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat 2008; doi:10.1016/j.jsat.2008.09.009.
9. Nguyen OK, Dore GJ, Kaldor JM, Hellard ME; ATAHC Protocol Steering Committee. Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study. Int J Drug Policy 2007;18:447-451.
10. Robaeys G, Van Vlierberghe H, Matheï C, Van Ranst M, Bruckers L, Buntinx F; BASL Steering Committee; Benelux Study Group. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol 2006;18:159-166. (Pubitemid 43361601)
11. Sylvestre DL, Zweben JE. IntegratingHCVservices for drug users: a model to improve engagement and outcomes. Int J Drug Policy 2007;18:406-410.